Literature DB >> 24395718

Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin.

Priyanka Ghosh1, Nicole K Brogden, Audra L Stinchcomb.   

Abstract

Microneedles (MNs), a physical skin permeation enhancement technique, facilitate drug delivery across the skin, thus enhancing the number of drugs that can be delivered transdermally in therapeutically relevant concentrations. The micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase the effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU), a HMGCoA reductase inhibitor, was used in this study to enhance the pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The study showed that using FLU as a pretreatment it is possible to enhance the pore lifetime of MN-treated skin and thus allow for sustained drug delivery. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  controlled release/delivery; fluvastatin; formulation vehicle; microneedles; pharmacokinetics; pore lifetime; spectroscopy; transdermal drug delivery; transepidermal water loss

Mesh:

Substances:

Year:  2014        PMID: 24395718     DOI: 10.1002/jps.23844

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Hydrogel-forming microneedles increase in volume during swelling in skin, but skin barrier function recovery is unaffected.

Authors:  Ryan F Donnelly; Karen Mooney; Maelíosa T C McCrudden; Eva M Vicente-Pérez; Luc Belaid; Patricia González-Vázquez; James C McElnay; A David Woolfson
Journal:  J Pharm Sci       Date:  2014-03-14       Impact factor: 3.534

2.  Laser facilitates week-long sustained transdermal drug delivery at high doses.

Authors:  Prateek Kakar; Zhuofan Li; Yibo Li; Yan Cao; Xinyuan Chen
Journal:  J Control Release       Date:  2020-01-07       Impact factor: 9.776

Review 3.  Recent advances of controlled drug delivery using microfluidic platforms.

Authors:  Sharma T Sanjay; Wan Zhou; Maowei Dou; Hamed Tavakoli; Lei Ma; Feng Xu; XiuJun Li
Journal:  Adv Drug Deliv Rev       Date:  2017-09-15       Impact factor: 15.470

4.  Solid Microneedles for Transdermal Delivery of Amantadine Hydrochloride and Pramipexole Dihydrochloride.

Authors:  Mylien T Hoang; Kevin B Ita; Daniel A Bair
Journal:  Pharmaceutics       Date:  2015-09-28       Impact factor: 6.321

5.  Repeat application of microneedles does not alter skin appearance or barrier function and causes no measurable disturbance of serum biomarkers of infection, inflammation or immunity in mice in vivo.

Authors:  Eva M Vicente-Perez; Eneko Larrañeta; Maelíosa T C McCrudden; Adrien Kissenpfennig; Shauna Hegarty; Helen O McCarthy; Ryan F Donnelly
Journal:  Eur J Pharm Biopharm       Date:  2017-05-03       Impact factor: 5.571

6.  Design and Development of Liquid Drug Reservoirs for Microneedle Delivery of Poorly Soluble Drug Molecules.

Authors:  Mary-Carmel Kearney; Peter E McKenna; Helen L Quinn; Aaron J Courtenay; Eneko Larrañeta; Ryan F Donnelly
Journal:  Pharmaceutics       Date:  2019-11-13       Impact factor: 6.321

Review 7.  Mini-Review: Assessing the Potential Impact of Microneedle Technologies on Home Healthcare Applications.

Authors:  Aaron McConville; Catherine Hegarty; James Davis
Journal:  Medicines (Basel)       Date:  2018-06-08

8.  Thermosensitive Gels Used to Improve Microneedle-Assisted Transdermal Delivery of Naltrexone.

Authors:  Kevin V Tobin; Jennifer Fiegel; Nicole K Brogden
Journal:  Polymers (Basel)       Date:  2021-03-18       Impact factor: 4.329

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.